Systematic review and meta-analysis of vismodegib for periocular and orbital basal cell carcinoma
Vismodegib shows response rates for periocular and orbital basal cell carcinoma
This systematic review and meta-analysis of 764 patients with periocular or orbital basal cell carcinoma found that vismodegib achieved comp…
A review of 764 patients found vismodegib helped shrink tumors, but side effects were common and led many to stop treatment.
